Prognostic Value of CV Biomarkers, End Points in Cancer Screening Trials, USPSTF on Breast Cancer Screening, and more
06/11/24 • 12 min
Editor’s Summary by Mary McGrae McDermott, MD, Deputy Editor of JAMA, the Journal of the American Medical Association, for the June 11, 2024, issue.
Editor’s Summary by Mary McGrae McDermott, MD, Deputy Editor of JAMA, the Journal of the American Medical Association, for the June 11, 2024, issue.
Previous Episode
Ponatinib vs Imatinib for Ph+ ALL, Cholesterol from Childhood to Adulthood and CVD Risk, Causal Inference, and more
Editor’s Summary by Preeti Malani, MD, MSJ, Deputy Editor of JAMA, the Journal of the American Medical Association, for the June 4, 2024, issue.
Next Episode
Krill Oil for Knee Osteoarthritis, EHR Prompts to Improve Antibiotic Selection, FTC Action on Prescription Drugs, and more
Editor’s Summary by Mary McDermott, MD, Deputy Editor of JAMA, the Journal of the American Medical Association, for the June 18, 2024, issue.
If you like this episode you’ll love
Episode Comments
Generate a badge
Get a badge for your website that links back to this episode
<a href="https://goodpods.com/podcasts/jama-editors-summary-117658/prognostic-value-of-cv-biomarkers-end-points-in-cancer-screening-trial-54076520"> <img src="https://storage.googleapis.com/goodpods-images-bucket/badges/generic-badge-1.svg" alt="listen to prognostic value of cv biomarkers, end points in cancer screening trials, uspstf on breast cancer screening, and more on goodpods" style="width: 225px" /> </a>
Copy